People's Hospital of Quzhou
Quzhou, Zhejiang, 324000, China
Location status: Recruiting
NCT Number: NCT06592859
This study is a single-center, randomized, double-blind, placebo-controlled clinical trial investigating a pharmacological intervention for aging. Its primary objective is to evaluate the efficacy of NMN while ensuring the safety of oral administration, with the aim of identifying effective strategies to delay aging and improve the quality of life in the elderly population. The main outcomes of this study are to characterize the patterns of NMN efficacy across different populations and to identify sensitive biomarkers that reflect responsiveness to the intervention.
Interested in participating?
Request InfoHealthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
:
Exclusion criteria
:
A) under 60 years old:
B) older than 60 years:
A) chemotherapy drugs (such as tamoxifen, adriamycin, mitoxantrone, bleomycin). B) antiplatelet drugs (e.g., clopidogrel/Plavix, dipyridamole/anglionide, ticlopidine/ticlopidine, except aspirin).
C) cholinesterase inhibitors for Alzheimer's disease (donepezil/alicept).
NMN Arm participants took one capsule (containing 350mg NMN or placebo) with breakfast daily for one year.
Placebo arm participants took one capsule (appearance and odor are the same as NMN) with breakfast daily for one year.
Time frame: Baseline, 6 months and 12 months
Change in biological age from baseline to 12 months, quantified using predefined multi-layer aging clock(s).
Biological age will be assessed using the following measures:
The primary endpoint will be defined as:
Change from baseline to 12 months in a prespecified composite biological age score, derived from the above aging clocks using a predefined integration method (e.g., standardized z-score aggregation or principal component-based integration).
A reduction in biological age is defined as a decrease in the composite biological age score.
Time frame: Baseline, 6 months and 12 months
NMN intervention-associated changes will be evaluated across predefined domains:
Circulating inflammatory markers (e.g., IL-6 [pg/mL], CRP [mg/L]) Improvement is defined as a reduction in these markers.
Gene expression, proteomic, and metabolomic profiles related to metabolism, immunity, and aging. These measures will be summarized using:
Predefined composite aging scoresm, biological ages, or principal component-based or pathway-level summaries, depending on the analysis framework.
Interested in participating?
Request InfoPeople's Hospital of Quzhou
Other
Quzhou Population Cohort Research Project (Aging Related Research: Intervention of Nicotinamide Mononucleotide in Middle-aged and Elderly People)
Acronym: NMNAGING
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07099053
Aging, Alzheimer Disease
Baltimore, Maryland, United States
View Trial DetailsNCT06851988
Aging, Behavior
New Taipei City, Taiwan
View Trial DetailsNCT07839572
Aging, Diastasis Recti Abdominis (DRA)
Gdansk, Pomeranian, Poland
View Trial DetailsNCT03896529
Aging, Anxiety
Atlanta, Georgia, United States
View Trial Details